Replies to post #5791 on Halozyme Therapeutics Inc (HALO)

[maumar]

I particularly like:

"At least 3 new Phase 3 and 1 Phase 2 clinical trial initiations by ENHANZE® collaboration partners."

This is obviously crucial for growth to be sustainable.

and

"Earnings Per Share (GAAP)


$0.60 to $0.75 "

Let's see how the market responds. Helen needs to cut costs dramatically so that most of the royalty revenues go to the bottom line.